Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cerebrolysin with or without rTMS for recovery after traumatic brain injury
ISRCTN10335247Phase 2Completed
- Sponsor
- EN: The foundation for the study of neuroscience and neuroregeneration (RO: Fundatia pentru Studiul Nanoneurostiintelor si Neuroregenerarii)
- Start
- Mar 2018
- Modality
- Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Native Peptides → Peptides, Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cerebrolysin in traumatic brain injury (TBI) (3 arms), sponsored by EN: The foundation for the study of neuroscience and neuroregeneration (RO: Fundatia pentru Studiul Nanoneurostiintelor si Neuroregenerarii). Primary endpoints: Stroop Color-Word Test at day 180, Montreal Cognitive Assessment at day 180 and 8 more. Started Mar 2018; status: completed.
02
Drugs
cerebrolysin
03
Conditions
traumatic brain injury (TBI)
Beyond the preview
Go deeper on ISRCTN10335247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN10335247.